MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, reported financial results for the quarter ended March 31, 2010. Product sales for the first quarter of 2010 increased 11% to $24.1 million, compared to $21.7 million for the first quarter of 2009. The 2010 first quarter results included $1.1 million from the sale of Vitomatrix™, a bone graft material used in dental products, and U.S. sales of $0.9 million of Cortoss™, the Company’s novel synthetic biomaterial that was cleared by the FDA in June 2009 for the treatment of vertebral compression fractures, and Aliquot, the Company’s Cortoss delivery device. There were no Vitomatrix sales in the first quarter of 2009. The $1.1 million in Vitomatrix sales occurred in March 2010 as part of an agreement to terminate our supply agreement for this product.
